Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy
Brief Summary: ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based chemotherapy in women with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Prognostic and predictive factors will be studied from tumour and blood samples.


Options:
A: Arm Label: Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: Triple-negative Breast Cancer: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: BRCA- positive Ovarian Cancer: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Non-Hodgkin's: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: Non-Hodgkin's: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Intervention Type: DRUG; Name: ABT-888; Assigned to Arm(s): BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide, Non-Hodgkin's: ABT-888 + Cyclophosphamide, Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): BRCA- positive Ovarian Cancer: Cyclophosphamide Alone, BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide, Non-Hodgkin's: ABT-888 + Cyclophosphamide, Non-Hodgkin's: Cyclophosphamide Alone, Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide, Triple-negative Breast Cancer: Cyclophosphamide Alone
B: Arm Label: Arm 1: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Niraparib | Arm Label: Arm 2: Niraparib and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Niraparib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 2: Niraparib and Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Arm 1: Niraparib, Arm 2: Niraparib and Bevacizumab
C: Arm Label: vargatef/Nintedanib; Type: EXPERIMENTAL; Interventions: Drug: vargatef | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vargatef; Assigned to Arm(s): vargatef/Nintedanib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Arm Label: Olaparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olaparib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib, Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Olaparib and Cediranib

Answer: D